Computer Models for Predicting Drug Absorption

Oral Drug Absorption: Prediction and Assessment, Second Edition

Volumn , Issue , 2016, Pages 338-355

  Parrott, Neil ^a   Lave, Thierry ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85136399465     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420077346-16     Document Type: Chapter

References (67)

1. Dressman JB, Amidon GL, Fleisher D. Absorption potential:estimating the fraction absorbed for orally administered compounds. J Pharm Sci 1985; 74:588-589.
2. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12:413-420.
3. FDA. Guidance for Industry-Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Food and Drug Administration. U.S. Department of Health and Human Services. Center for Drug Evaluation and Research (CDER), 1997.
4. FDA. Guidance for Industry-Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.
5. Yu LX, Lipka E, Crison JR, et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 1996; 19:359-376.
6. Grass GM. Simulation models to predict oral drug absorption from in vitro data. Adv Drug Delivery Rev 1997; 23:190-219.
7. Nicolaides E, Symillides M, Dressman JB, et al. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001; 18:380-388.
8. Fotaki N, Symillides M, Reppas C. Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration. Eur J Pharm Sci 2005; 26:324-333.
9. Rausl D, Fotaki N, Zanoski R, et al. Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. J Pharm Pharmacol 2006; 58:827-836.
10. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50:S41-S67.
11. Dressman JB, Fleisher D. Mixing tank model for predicting dissolution rate control of oral absorption. J Pharm Sci 1986; 75:109-116.
12. Johnson KC. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev Ind Pharm 2003; 29:833-842.
13. Willmann S, Lippert S, Severstre J, et al. PK-Sim: a physiologically based pharmacokinetic '‘whole-body’' model. BioSilico 2003; 1:121-124.
14. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996; 140:111-118.
15. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186:119-125.
16. Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res 1999; 16:1883-1887.
17. van de Waterbeemd H, Lennernäs H, Artursson P. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. Weinheim: Wiley-VCH, 2003.
18. Lennernas H. Human intestinal permeability. J Pharm Sci 1997; 87:403-410.
19. Kansy M, Avdeef A, Fischer H. Advances in screening for membrane permeability:high-resolution PAMPA for medicinal chemists. Drug Discov Today 2004; 1:349-355.
20. Avdeef A. Absorption and Drug Development-Solubility Permeability and Charge State: Wiley-IEEE, 2003.
21. Alsenz J, Haenel E. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm Res 2003; 20:1961-1969.
22. Cyprotex. Cloe Predictive Human Intestinal Absorption Model. Available at: http:// www.cyprotex.com, Accessed May 2008.
23. Jamei M, Yang J, Turner D, et al. A Novel Physiologically-Based Mechanistic Model for Predicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model. 4th World Conference on Drug Absorption, Transport and Delivery, Kanazawa, Japan 2007.
24. Jianzhuo Wang Flanagan DR. General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. J Pharm Sci 1999; 88:731-738.
25. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6:140-148.
26. Yang J, Jamei M, Yeo KR, et al. Prediction of intestinal first-pass drug metabolism. Curr Drug Metabol 2007; 8:676-684.
27. Willmann S, Schmitt W, Keldenich Jor, et al. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 2003; 20:1766-1771.
28. Ni P, Ho N, Fox J, et al. Theoretical-model studies of intestinal drug absorption. 5. Non-steady-state fluid-flow and absorption. Int J Pharm 1980; 5:33-47.
29. Willmann S, Schmitt W, Keldenich J, et al. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004; 47:4022-4031.
30. Willmann S, Edginton AN, Dressman JB. Development and validation of a physiology- based model for the prediction of oral absorption in monkeys. Pharm Res 2007; 24:1275-1282.
31. Lu ATK, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res 1993; 10:1308-1314.
32. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989; 51:9-17.
33. Parrott N, Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 2002; 17:51-61.
34. FDA. Innovation or stagnation: challenge and opportunity on the critical path to new medical products, 2004.
35. Lave T, Parrott N, Grimm HP, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007; 37:1295-1310.
36. Barrett JS. Model based drug development applied to oncology. Expert Opin Drug Discov 2007; 2:185-209.
37. d’Yvoire MB, Prieto P, Blaauboer BJ, et al. Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda. ATLA 2007; 35:661-671.
38. Parrott N, Paquereau N, Coassolo P, et al. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005; 94:2327-2343.
39. Alsenz J, Kansy M. High throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev 2007; 59:546-567.
40. Mithani SD, Bakatselou V, TenHoor CN, et al. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 1996; 13:163-167.
41. De Buck SS, Sinha VK, Fenu LA, et al. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 2007; 35:649-659.
42. Alsenz J, Meister E, Haenel E. Development of a partially automated solubility screening (pass) assay for early drug development. J Pharm Sci 2007; 96:1748-1762.
43. Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 1996; 13:1795-1798.
44. Sun D, Yu LX, Hussain MA, et al. In vitro testing of drug absorption for drug “developability” assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Dev 2004; 7:75-85.
45. Ding X, Rose JP. Absorbable Dose Prediction of Select Post-Phase I Trial Internal Compounds. AAPS Annual Meeting and Exposition, 2007.
46. Parrott N, Lave T. Applications of physiologically based absorption models in Drug Discovery and Development. Mol Pharm 2008; 5:760-775.
47. Dannenfelser R-M, He H, Joshi Y, et al. Development of clinical dosage forms for a poorly water soluble drug. I: application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 2004; 93:1165-1175.
48. Kuentz M, Nick S, Parrott N, et al. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 2006; 27:91-99.
49. Jones H, Parrott N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharm 2006; 45:511-542.
50. De Buck SS, Sinha VK, Fenu LA, et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35:1766-1780.
51. FDA. Guidance for Industry Food-Effect Bioavailability and Bioequivalence Studies.
52. Jones H, Parrott N, Ohlenbusch G, et al. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharm 2006; 45:1213-1226.
53. Kesisoglou F, Wu Y, Chin A. Prediction of Micronized Aprepitant Food Effect Through Absorption Modeling. AAPS Annual Meeting and Exposition, 2007.
54. Wu Y, Loper A, Landis E, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004; 285:135-146.
55. Kalantzi L, Persson E, Polentarutti B, et al. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 2006; 23:1373-1381.
56. Aburub A, Risley DS, Mishra D. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int J Pharm 2008; 347:16-22.
57. Lukácová V. Modeling of cilostazol absorption and pharmacokinetics in beagle dogs and design of in vitro dissolution experiment to model the in vivo absorption. AAPS Annual Meeting and Exposition, 2006.
58. Jinno J. Effect of particle size reduction on dissolution and oral absorption of a poorly water soluble drug, cilostazol, in beagle dogs. J Control Release 2006; 111:56-64.
59. Kesisoglou F, Wu Y, Manser K, et al. Assessment of effect of API properties on in vivo dissolution and bioavailability through absorption modeling. AAPS Annual Meeting and Exposition, 2007.
60. Lindahl A, Sjoberg A, Bredberg U, et al. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol Pharm 2004; 1:347-356.
61. Wei H, Dalton C, Maso MD, et al. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur J Pharm Biopharm 2008; 69:1046-1056. doi: 10.1016/j.ejpb.2008.01.026.
62. Tubic-Grozdanis M, Bolger M, Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J 2008; 10:213-226.
63. Tubic M, Wagner D, Spahn-Langguth H, et al. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res 2006; 23:1712-1720.
64. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20:1595-1599.
65. Bolger MB, Lukacova V, Lloyd R. GastroPlus PBPK Simulation of Simvastatin:Uptake transport by hepatic serosal OATP, biliary efflux transport by apical Pgp, and metabolism by CYP3A4 in gut and liver. Poster at BioMed-Transporters-2007-Bern, 2007.
66. Woltosz WS, Chittenden J, Bolger MB. Simulation of PK Profiles from In Vitro Data and In Silico Estimation of Tissue-Plasma Partition Coefficients using GastroPlus-PBPK. Poster-AAPS, 2005.
67. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report. AAPS PharmSci 2004; 6:E6.